July 12, 2017

IntegriChain Surpasses 100 Bio/Pharma Customers for Distribution, Patient, and Payer Data and Analytics Solutions

– All Top-10 Bio/Pharma Manufacturers Use the IntegriChain Cloud –

– Accelerated YTD Pace with 19 New Manufacturers Signed –

Philadelphia, PA, July 12, 2017 – IntegriChain, a leading healthcare technology company delivering distribution, patient, and payer data and analytics solutions, today announced that it has surpassed 100 bio/pharmaceutical manufacturer customers for its cloud-based platform. The Company has accelerated its customer acquisition activities, signing 19 new customers to date in 2017. Presently, all top-10 and 16 of the top-20 bio/pharma manufacturers use IntegriChain solutions.

“2017 is proving to be a very strong year in IntegriChain’s rapid growth cycle, and we are delivering data and analytics that allow bio/pharma commercial operations teams to optimize the patient journey to more and more manufacturers,” said Kevin Leininger, Co-Founder and CEO. “Our April acquisition of PharmaMetrics expanded our platform offerings to include leading payer solutions, and our rapid pace of signing new customers this year has been unprecedented. With this growth, we are well-situated to be a valued partner to a significantly larger portion bio/pharma industry and the leading data and analytics provider for distribution, patient access, and market access challenges. We thank our customers for their trust in us and our cloud platform, and we look forward to continuing to develop solutions that address their commercial challenges.”

About IntegriChain
IntegriChain is a rapidly growing healthcare technology company, offering the leading data and analytics cloud for distribution, patient, and payer solutions. These solutions empowers bio/pharma commercial operations teams to optimize distribution, patient access, and market access by leveraging insights from IntegriChain’s unmatched factory-to-patient data platform. IntegriChain delivers the data and analytics foundation for more efficient and service-oriented channel models for mature product categories as well as for innovative products that must balance significant therapeutic benefit with out-of-pocket costs and benefit hurdles. Today IntegriChain is the trusted partner for all top-10 bio/pharmaceutical companies, 16 of the top-20 life science companies, and more than 80 other suppliers, totaling more than $250 billion in annual US commerce. IntegriChain is backed by Accel-KKR, a leading Silicon Valley technology private equity firm. For more information, visit visit and our blog, and follow us on Twitter @IntegriChain and LinkedIn.

Jennifer Guinan | Sage Strategic Marketing | 610.410.8111 |

adapt analytics bars bell books magnify chart connections marker meds pills search computer paper webcast article blog ebook distribute hand payer heart market Asset 69 Asset 65 Asset 64 Asset 68 Asset 67 Asset 66 Asset 63 decrease expand builder close dart data demand increase index lock locked meter open order pharma pill plot prescription revenue scorecard service shake unlocked Asset 61 Asset 60 Asset 71 icon-distribution-distribution-contract-management icon-distribution-distribution-data-refinery icon-distribution-inventory-analytics icon-distribution-retail-analytics icon-patient-patient-data-refinery icon-patient-patient-services-analytics icon-patient-specialty-pharmacy-analytics icon-payer-340b-analytics icon-payer-analytics icon-payer-g2n icon-payer-government-pricing icon-payer-rebate-management Asset 1 hand hand hand hand hand hand hand hand hand hand hand paper article